期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 8, 期 15, 页码 2615-2624出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.8.15.2615
关键词
MAO-B inhibitor; motor fluctuation; Parkinson's disease; Zydis selegiline
Selegiline, a selective monciamine oxidase-B inhibitor, has been used for decades in the treatment of Parkinson's disease. The recent development of an orally disintegrating dosage form using Zydis technology allows pregastric drug absorption and, thus, greatly improving the pharmacodynamic and pharmacokinetic drug profiles. This new formulation provides higher drug bioavailability and a substantially reduced concentration of active metabolites. As an adjunct to levoclopa, Zydis selegiline is shown to be a safe and effective therapy in patients with motor fluctuations and wearing off. This review outlines the advantages of a Zydis formulation in Parkinson's disease and the evidence supporting the use of Zydis selegiline for motor fluctuations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据